David's mailing address filed with the SEC is 1601 Trinity St Bldg. A, Austin, TX 78712, USA.
Over the last 7 years, insiders at Genprex Inc have traded over 0$ worth of Genprex Inc stock and bought 156,300 units worth 607,092$ . The most active insiders traders include Ryan M. Confer、Christy M. Nance、Jack A Roth. On average, Genprex Inc executives and independent directors trade stock every 205 days with the average trade being worth of 14,575$. The most recent stock trade was executed by John Rodney Varner on 21 April 2023, trading 19,000 units of GNPX stock currently worth 20,140$.
genprex is mapping the future of cancer care. genprex's mission is to address the unmet medical needs of a growing population of cancer patients worldwide, through the development of a novel class of cancer drugs: immunogene therapy. our revolutionary clinical-stage products work synergistically with other approved and pipeline drugs to expand clinical indications for various cancers. about oncoprex® and lung cancer lung cancer is the second most common cancer in the u.s. but the leading cause of cancer death. there are approximately 225,000 new lung cancer cases in the u.s. per year and 1.8 million worldwide. the 5-year survival rate of stage iv non-small cell lung cancer (nsclc) is less than 1%, and treatment options beyond chemotherapy are lacking. approved nsclc targeted treatment options outside of chemo/radiation therapies only benefit a minority of patients. oncoprex® may now fill that gap by offering a targeted treatment option for a majority of nsclc patients. oncoprex® is cur
Genprex Inc executives and other stock owners filed with the SEC include: